T-DM1 is also used routinely in the adjuvant treatment setting for those patients with early stage HER2 positive breast cancer who are at higher risk of disease recurrence based on the presence of residual disease at surgery following neoadjuvant systemic therapy (10). This evidence concerns the gene ERBB2 and breast cancer.